Bank of New York Mellon’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-133,225
| Closed | -$212K | – | 4335 |
|
|
2024
Q1 | $212K | Sell |
133,225
-5,865
| -4% | -$8.7K | ﹤0.01% | 3913 |
|
|
2023
Q4 | $119K | Sell |
139,090
-55
| -0% | -$48 | ﹤0.01% | 4057 |
|
|
2023
Q3 | $149K | Sell |
139,145
-391
| -0.3% | -$809 | ﹤0.01% | 4030 |
|
|
2023
Q2 | $361K | Buy |
139,536
+6,842
| +5% | +$24.4K | ﹤0.01% | 3754 |
|
|
2023
Q1 | $541K | Sell |
132,694
-721
| -0.5% | -$3.33K | ﹤0.01% | 3454 |
|
|
2022
Q4 | $670K | Sell |
133,415
-17,214
| -11% | -$108K | ﹤0.01% | 3399 |
|
|
2022
Q3 | $1.97M | Buy |
150,629
+19,840
| +15% | +$300K | ﹤0.01% | 2867 |
|
|
2022
Q2 | $1.68M | Sell |
130,789
-1,725
| -1% | -$23.9K | ﹤0.01% | 2936 |
|
|
2022
Q1 | $2.02M | Buy |
132,514
+3,893
| +3% | +$60.7K | ﹤0.01% | 2939 |
|
|
2021
Q4 | $2.28M | Buy |
128,621
+11,387
| +10% | +$218K | ﹤0.01% | 2914 |
|
|
2021
Q3 | $2.46M | Buy |
117,234
+15,843
| +16% | +$349K | ﹤0.01% | 2863 |
|
|
2021
Q2 | $2M | Buy |
101,391
+21,635
| +27% | +$506K | ﹤0.01% | 2984 |
|
|
2021
Q1 | $2.32M | Sell |
79,756
-3,399
| -4% | -$95.2K | ﹤0.01% | 2841 |
|
|
2020
Q4 | $2.52M | Sell |
83,155
-1,891
| -2% | -$41.4K | ﹤0.01% | 2707 |
|
|
2020
Q3 | $1.35M | Buy |
85,046
+3,857
| +5% | +$70.4K | ﹤0.01% | 2929 |
|
|
2020
Q2 | $1.6M | Sell |
81,189
-1,106
| -1% | -$21.1K | ﹤0.01% | 2806 |
|
|
2020
Q1 | $1.01M | Buy |
82,295
+23,567
| +40% | +$385K | ﹤0.01% | 2970 |
|
|
2019
Q4 | $1.08M | Buy |
58,728
+33,791
| +136% | +$494K | ﹤0.01% | 3207 |
|
|
2019
Q3 | $345K | Buy |
24,937
+12,928
| +108% | +$194K | ﹤0.01% | 3725 |
|
|
2019
Q2 | $176K | Buy |
+12,009
| New | +$176K | ﹤0.01% | 3945 |
|
Bank of New York Mellon's NGM Position: Q2 2024 in Review
Bank of New York Mellon sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 133,225 shares — an estimated $212K sold.
Bank of New York Mellon first reported a position in NGM in Q2 2019 and held it in 20 quarters. The position peaked at $2.52M in Q4 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Bank of New York Mellon reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 133,225 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $212K.
- Bank of New York Mellon first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 20 quarters.
- Bank of New York Mellon's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.52M in Q4 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.